NEW YORK, April 18, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Generic and innovative drugs market in Central Europe 2012
Comparative analysis, reimbursement policies and development forecasts for 2012-2014
Generic and innovative drugs market in Central Europe 2012, Comparative analysis, reimbursement policies and development forecasts for 2012-2014 details the current market structures, policies and procedures for reimbursement in Poland, Romania, Slovakia, the Czech Republic, Hungary and Bulgaria. This timely report features complete information on new legislative developments occurring in each country and compiles accurate forecasts for the market over the next two years based on the projected impact of these new regulatory frameworks.
It helps readers to gain a comprehensive understanding of the marketplace by laying the groundwork with coverage of market values for generic and innovative medicines, therapies and devices from 2009 forward to 2014. It describes market sizes and shares of the pharmaceutical markets for these valuable segments in each country and supplies corresponding comparative analysis.
Fresh content includes dynamic coverage of the reimbursement policies and processes for each country, and discusses changes in pricing, VAT rates, reimbursement levels, data on patent longevity, expiration terms, SPCs and data exclusivity periods. The report names the top selling products in each category, their prices and industry markups. It also explains in detail the issue of counterfeit medications, the size of the market share they occupy, and the ways in which each country regulates manufacture, distribution and sale.
The report examines the market for generic and innovative drugs in the Central European region from the viewpoint of physicians and patients, revealing their opinions and predispositions toward or against the use of these products. It provides detailed corporate profiles of the manufacturers and distributors of these types of medications in each of the covered countries.
Generic and innovative drugs market in Central Europe 2012, Comparative analysis, reimbursement policies and development forecasts for 2012-2014 provides vital information for professionals seeking to conduct business, prepare strategy or plan investments in these regional markets.
I. Report methodology p. 13
II. Executive summary p. 19
III. Characteristics of generic and innovative drug markets in Central European countries p. 27
IV. Best-selling drugs in Central Europe p. 93
V. Counterfeit products p. 109
VI. Reimbursement and pricing policies in Central Europe p. 113
VII. Key manufacturers p. 195
VIII. List of graphs p. 289
IX. List of tables p. 297
X. About PMR p. 301
XI. Contact PMR p. 302
To order this report:
Check our Industry Analysis and Insights
Email: [email protected]
Intl: +1 805-652-2626